Key takeaway: Anupam Rasayan India Limited's investor presentation for Q1 FY27 reported a consolidated total revenue of ₹6,675 million, reflecting a year-on-year growth of 36%. The presentation highlighted the addition of three new products, bringing the total to over 125. Consolidated EBITDA was reported at ₹1,749 million, a 35% increase year-on-year, while profit after tax rose by 6% to ₹512 million. The company achieved a significant milestone by commercializing Ethyl Trifluoroacetate (ETFA) using flow chemistry. Management noted a signed Letter of Intent with BASQUEVOLT, S.A. for a potential revenue opportunity of up to $300 million over ten years. The acquisition of Jayhawk Fine Chemicals was also mentioned as a strategic move to enhance manufacturing capabilities. Overall, the presentation emphasized strong growth across various segments and ongoing strategic initiatives to strengthen the company's market position.

Key takeaway: Anupam Rasayan India Limited reported a landmark year in FY '26, achieving its highest ever revenue, driven by strong execution across key business verticals and a diversified product portfolio. Management highlighted a threefold increase in revenue from high-performance materials and a 15-fold increase in pharmaceutical revenue over the past four years. The company has reduced its dependence on agrochemicals from 76% to 55% of total revenue. Management announced the acquisition of Jayhawk Fine Chemicals to enhance its U.S. manufacturing footprint and capabilities, and a definitive agreement to acquire a significant stake in Bliss GVS Pharma to strengthen its pharmaceutical platform. Financially, the company reported a 65% year-on-year increase in revenue, with a consolidated profit after tax of INR 222 crores. Management expressed confidence in long-term growth, supported by recent acquisitions and operational efficiencies.

Key takeaway: Anupam Rasayan India Limited submitted an investor presentation regarding its acquisition of Bliss GVS Pharma Limited. The presentation highlighted Bliss GVS Pharma's capabilities, including its US FDA approval for a suppository unit and its extensive range of therapeutic segments. Management reported a robust performance trend for Bliss GVS Pharma, with significant revenue and EBITDA growth projected. The presentation outlined strategic plans for expansion into various therapeutic areas and the CDMO business, emphasizing the potential for increased capacity utilization and forward integration. The transaction details included an open offer for a controlling stake in Bliss GVS Pharma, funded through a term loan and non-controlling equity instruments. The document also noted ongoing and executed capital expenditure projects aimed at enhancing manufacturing capabilities and entering regulated markets.

Key takeaway: Anupam Rasayan India Limited's investor presentation for Q4 and FY26 highlighted the company's highest-ever annual performance, with total revenue reaching ₹23,836 million, reflecting a year-on-year growth of 65%. The presentation reported a successful acquisition of Jayhawk Fine Chemicals, enhancing the company's global manufacturing footprint and chemistry capabilities. Management noted the addition of new multinational customers and the launch of three new products during the year. The company achieved an operating cash flow of ₹3,343 million, indicating improved operational efficiency. The presentation also detailed a definitive agreement to acquire a controlling stake in Bliss GVS Pharma, aimed at expanding capabilities in the pharmaceutical value chain. Overall, the document emphasized strong business momentum and strategic growth initiatives across various segments, including Performance Materials and Pharmaceuticals.

Key takeaway: Anupam Rasayan India Limited reported consolidated revenue of INR 1,730 crores for the nine months ended December 31, 2025, reflecting an 84% year-on-year growth. EBITDA was INR 402 crores, up 53% year-on-year, and PAT reached INR 166 crores, marking a 71% increase. For Q3 FY26, revenue was INR 512 crores, a 31% year-on-year rise, with EBITDA at INR 130 crores and PAT at INR 61 crores, both showing growth compared to the previous year. Management highlighted strong performance in the Pharma segment, which contributed 19% of sales, and noted a recovery in the Agro segment. The company announced a definitive agreement to acquire Jayhawk Fine Chemicals, enhancing its manufacturing presence in the US and expanding its capabilities in high-value markets. Management emphasized a focus on commercializing pipeline molecules and improving supply chain resilience.